Ferring B.v.

Ferring International Center Sa.

Bio-technology General (israel) Ltd.

Daniel Plaksin

Ian Cottingham

Richard White

Jérémy Duboeuf

Avigdor Levanon

Rachel Guy

Varinder Ahuja

Tuvia Peretz

Ganeshchandra Sonavane

Parag Lokhande

Ayelet Grinhut

Jenny Aharanov

Yocheved Hagay

Janette Lazarovits

Orly Lifshitz

Devendra Kantilal Jain

Esther Szanton

Richard Boyd White

Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and optionally follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.

Pharmaceutical preparation comprising recombinant HCG

Preparations including recombinant FSH (rFSH).

Pharmaceutical preparation

A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.

Selective IL-6-trans-signalling inhibitor compositions

Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises &#x3b1;2,3- and &#x3b1;2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using &#x3b1;2,3-sialyltransferase.

Pharmaceutical preparation comprising recombinant hCG

The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.

Fast disintegrating pharmaceutical composition

The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include &#x3b1;2,3, &#x3b1;2,6, and, optionally, &#x3b1;2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6&#xae; cell line.

Pharmaceutical preparation comprising recombinant HcG

A host cell characterized in that it comprises integrated into its genome a sequence coding for the a chain of hCG, and use of the host cell to produce recombinant hCG.

Optimized nucleic acid sequences coding for the alpha-chain of human chorionic gonadotropin

Polyethylene glycol modified human chorionic gonadotropin (hCG), preparations thereof, compositions thereof, and methods of preparation and use thereof are described.

Recombinant FSH including alpha 2,3- and alpha 2,6-sialylation

The present disclosure describes recombinant follicle stimulating hormone (FSH) and methods for the production thereof. The recombinant FSH can include &#x3b1;2,3, &#x3b1;2,6, and, optionally, &#x3b1;2,8 sialylation. The recombinant FSH can be produced in a human cell line such as a PER.C6&#xae; cell line.

Growing community of inventors

St. Prex, Switzerland

Daniel Plaksin